BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 25197009)

  • 1. Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major.
    Casale M; Citarella S; Filosa A; De Michele E; Palmieri F; Ragozzino A; Amendola G; Pugliese U; Tartaglione I; Della Rocca F; Cinque P; Nobili B; Perrotta S
    Am J Hematol; 2014 Dec; 89(12):1102-6. PubMed ID: 25197009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
    Poggi M; Sorrentino F; Pugliese P; Smacchia MP; Daniele C; Equitani F; Terlizzi F; Guitarrini MR; Monti S; Maffei L; Losardo A; Pasin M; Toscano V
    Ann Hematol; 2016 Apr; 95(5):757-63. PubMed ID: 26957357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre.
    Gamberini MR; De Sanctis V; Gilli G
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():158-69. PubMed ID: 19337172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
    Wang CH; Wu KH; Tsai FJ; Peng CT; Tsai CH
    Hemoglobin; 2006; 30(2):257-62. PubMed ID: 16798651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of genotype on endocrine complications in thalassaemia major.
    Skordis N; Michaelidou M; Savva SC; Ioannou Y; Rousounides A; Kleanthous M; Skordos G; Christou S
    Eur J Haematol; 2006 Aug; 77(2):150-6. PubMed ID: 16800840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrine complications in patients with Thalassaemia Major.
    Toumba M; Sergis A; Kanaris C; Skordis N
    Pediatr Endocrinol Rev; 2007 Dec; 5(2):642-8. PubMed ID: 18084158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of ICL670, a once-daily oral iron chelator in a phase III clinical trial of beta-thalassemia patients with transfusional iron overload.
    Galanello R
    Ann N Y Acad Sci; 2005; 1054():183-5. PubMed ID: 16339664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrinopathies, metabolic disorders, and iron overload in major and intermedia thalassemia: serum ferritin as diagnostic and predictive marker associated with liver and cardiac T2* MRI assessment.
    Chirico V; Rigoli L; Lacquaniti A; Salpietro V; Piraino B; Amorini M; Salpietro C; Arrigo T
    Eur J Haematol; 2015 May; 94(5):404-12. PubMed ID: 25200112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low bone mineral density in adolescents with beta-thalassemia.
    Vogiatzi MG; Autio KA; Mait JE; Schneider R; Lesser M; Giardina PJ
    Ann N Y Acad Sci; 2005; 1054():462-6. PubMed ID: 16339698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of deferasirox on renal, cardiac and hepatic iron load in patients with β-thalassemia major: preliminary results.
    Unal S; Hazirolan T; Eldem G; Gumruk F
    Pediatr Hematol Oncol; 2011 Apr; 28(3):217-21. PubMed ID: 21083355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine.
    Pennell DJ; Porter JB; Piga A; Lai YR; El-Beshlawy A; Elalfy M; Yesilipek A; Kilinç Y; Habr D; Musallam KM; Shen J; Aydinok Y;
    Am J Hematol; 2015 Feb; 90(2):91-6. PubMed ID: 25345697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.
    Alavi S; Ebadi M; Ghazizadeh F; Arzanian MT; Shamsian B; Abdollah Gorji F
    Pediatr Hematol Oncol; 2014 Feb; 31(1):76-86. PubMed ID: 24383712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia.
    Karimi M; Arandi N; Haghpanah S; Ansari S; Azarkeyvan A; Bordbar M; Safaei S
    Hemoglobin; 2015; 39(5):327-9. PubMed ID: 26114738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years.
    Deugnier Y; Turlin B; Ropert M; Cappellini MD; Porter JB; Giannone V; Zhang Y; Griffel L; Brissot P
    Gastroenterology; 2011 Oct; 141(4):1202-11, 1211.e1-3. PubMed ID: 21741344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis.
    Shashaty G; Frankewich R; Chakraborti T; Choudary J; Al-Fayoumi S; Kacuba A; Castillo S; Robie-Suh K; Rieves D; Weiss K; Pazdur R
    Oncology (Williston Park); 2006 Dec; 20(14):1799-1806, 1811; discussion 1811-13, 1817. PubMed ID: 17263129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective.
    Karnon J; Tolley K; Vieira J; Chandiwana D
    Clin Drug Investig; 2012 Dec; 32(12):805-15. PubMed ID: 23026844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of long-term iron chelation therapy on growth and endocrine functions in thalassaemia.
    De Sanctis V; Roos M; Gasser T; Fortini M; Raiola G; Galati MC;
    J Pediatr Endocrinol Metab; 2006 Apr; 19(4):471-80. PubMed ID: 16759032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden.
    Voskaridou E; Komninaka V; Karavas A; Terpos E; Akianidis V; Christoulas D
    Transfusion; 2014 Mar; 54(3):646-9. PubMed ID: 23834310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies.
    Voskaridou E; Christoulas D; Terpos E
    Br J Haematol; 2011 Sep; 154(5):654-6. PubMed ID: 21615376
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 25.